HNHA (N-hydroxy-7-(2-naphthylthio) heptanomide) is a novel HDAC inhibitor that shows better pharmacological properties than a known HDACIs present in the human fibrosarcoma cell - SAHA (Suberoylanilide Hydroxamic Acid).

Heptanomide, HNHA

HNHA arrested the cell cycle at the G1/S phase via p21 induction, which led to profound inhibition of cancer cell growth in vitro. In addition, HNHA-treated cells showed markedly decreased levels of VEGF and HIF-1α than SAHA and FUMA (Fumagillin) when accompanied by increased histone acetylation. HNHA significantly inhibited tumor growth in an in vivo mouse xenograft model. HNHA-treated mice survived significantly longer than FUMA- and SAHA-treated mice.

Synonyms: Heptanomide; N-hydroxy-7-(2-naphthalenylthio)-heptanamide
Technical Data: Molecular Weight - 303.43; Molecular formula - C17H21NO2S; CAS No - 926908-04-5

Ordering Information: Product Number - EC-000.2463
Price and Availability: Inquire
This product is also available to buy in bulk quantities.

1. Park KC, Kim SW, Park JH., et al. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo. Cancer Sci. 2011 Feb;102(2):343-50.
2. Kim, J.H., Kim, J.H., Oh, M., et al. N-hydroxy-7-(2-naphthylthio) heptanomide inhibits retinal and choroidal angiogenesis. Mol Pharm 6(2) 513-519 (2009).
3. Kim, D.H., Lee, J., Kim, K.N., et al. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun 356 233-238 (2007).

Related Products:

Related Products: Suberoylanilide Hydroxamic Acid; MS-275 (Entinostat); CI-994 (Tacedinaline); BML-210; M344; MGCD0103 (Mocetinostat); PXD101 (Belinostat); LBH-589 (Panobinostat); Tubastatin A; Scriptaid; NSC 3852; NCH 51; BML-281; CBHA; Salermide; Pimelic Diphenylamide; ITF2357 (Givinostat); PCI-24781; APHA Compound 8; Droxinostat; SB939.

Related service: collection of Histone Deacetylase Inhibitors.